22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting Post navigationPreviousPrevious post:Live webcast on masitinib in combination with isoquercetine for the treatment of COVID-19 on Monday May 11, 2020NextNext post:Presentation of the results from AB8939 preclinical program in AML in EHA 2020 Annual CongressRelated PostsBoursorama interview of Alain Moussy, CEO of AB ScienceDecember 23, 2020Capital raise for a total amount of 15 million eurosDecember 21, 2020Results from phase 2B/3 study evaluating masitinib in Alzheimer’s diseaseDecember 18, 2020Masitinib in Alzheimer’s Disease Webcast PresentationDecember 17, 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020December 17, 2020Corrective press release regarding adverse events information from study AB09004December 17, 2020